Research Article
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
Table 1
Patient characteristics: MM patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*One patient was in PR at first mobilization; however, he developed disease progression by the time he went through the plerixafor mobilization. The patient did not go through ASCT, and he was excluded from survival analysis. **At 3 months of evaluation posttransplant, patients were offered maintenance therapy with thalidomide. Note. The results show number of patients in each category unless indicated otherwise. |